UK Markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.36-0.48 (-1.46%)
At close: 04:00PM EST
32.00 -0.36 (-1.11%)
After hours: 06:02PM EST

Denali Therapeutics Inc.

161 Oyster Point Boulevard
2nd Floor
South San Francisco, CA 94080
United States
650 866 8548

Full-time employees360

Key executives

NameTitlePayExercisedYear born
Dr. Ryan J. Watts Ph.D.Co-Founder, Pres, CEO & Director1.25MN/A1976
Dr. Alexander O. Schuth M.D.Co-Founder, COO & Sec.820.32kN/A1973
Dr. Marc Tessier-Lavigne Ph.D.Co-Founder, Chairman of Scientific Advisory Board & Independent Director59.5kN/A1960
Mr. Steve Edward KrognesCFO & Treasurer882.96kN/A1968
Dr. Carole HoChief Medical Officer & Head of Devel.835.08k1.88M1973
Mr. Tyler M. NielsenVP of Corp. Fin.N/AN/A1978
Dr. Dana AndersenChief Technical and Manufacturing OfficerN/AN/AN/A
Mr. Joe LewcockChief Scientific OfficerN/AN/AN/A
Dr. Laura HansenVP of Investor RelationsN/AN/AN/A
Mr. Chris WalshAssociate Gen. CounselN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate governance

Denali Therapeutics Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.